AG˹ٷ

STOCK TITAN

[6-K] Cardiol Therapeutics Inc. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세�:
Réécrivez le texte suivant :
Schreibe den folgenden Text um:
Positive
  • None.
Negative
  • None.
Riscrivi il testo seguente:
Reescribe el siguiente texto:
다음 텍스트를 다시 작성하세�:
Réécrivez le texte suivant :
Schreibe den folgenden Text um:

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F


SUBMITTED HEREWITH

Exhibits

Exhibit   Description
   
99.1   News Release dated August 6, 2025 - Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx™ in Acute Myocarditis


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  CARDIOL THERAPEUTICS INC.
  (Registrant)
     
Date: August 6, 2025 By: /s/ Chris Waddick
   
    Chris Waddick
  Title: Chief Financial Officer


FAQ

What information is available?

This document appears to contain limited substantive content.
Cardiol Therapeu

NASDAQ:CRDL

CRDL Rankings

CRDL Latest News

CRDL Latest SEC Filings

CRDL Stock Data

111.58M
78.75M
4.35%
9.87%
2.09%
Drug Manufacturers - Specialty & Generic
Healthcare
Canada
Oakville